



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Drug resistance mutations in drug-naïve HIV type 1 subtype C-infected individuals from rural Malawi

Citation for published version:

Bansode, V, Drebert, ZJ, Travers, SAA, Banda, E, Molesworth, A, Crampin, A, Ngwira, B, French, N, Glynn, JR & McCormack, GP 2011, 'Drug resistance mutations in drug-naïve HIV type 1 subtype C-infected individuals from rural Malawi', *Aids research and human retroviruses*, vol. 27, no. 4, pp. 439-44.
<https://doi.org/10.1089/aid.2010.0203>

Digital Object Identifier (DOI):

[10.1089/aid.2010.0203](https://doi.org/10.1089/aid.2010.0203)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Publisher's PDF, also known as Version of record

Published In:

Aids research and human retroviruses

Publisher Rights Statement:

Copyright 2011, Mary Ann Liebert, Inc.

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Drug Resistance Mutations in Drug-Naive HIV Type 1 Subtype C-Infected Individuals from Rural Malawi

Vijay Bansode,¹ Zuzanna J. Drebert,¹ Simon A.A. Travers,^{1,2} Emmanuel Banda,³ Anna Molesworth,^{3,4} Amelia Crampin,^{3,4} Bagrey Ngwira,^{3,4} Neil French,^{3,4} Judith R. Glynn,³ and Grace P. McCormack¹

Abstract

In this preliminary study we show that in 2008, 3 years after antiretroviral therapy was introduced into the Karonga District, Malawi, a greater than expected number of drug-naive individuals have been infected with HIV-1 subtype C virus harboring major and minor drug resistance mutations (DRMs). From a sample size of 40 reverse transcriptase (RT) consensus sequences from drug-naive individuals we found five showing NRTI and four showing NNRTI mutations with one individual showing both. From 29 protease consensus sequences, again from drug-naive individuals, we found evidence of minor DRMs in three. Additional major and minor DRMs were found in clonal sequences from a number of individuals that were not present in the original consensus sequences. This clearly illustrates the importance of sequencing multiple HIV-1 variants from individuals to fully assess drug resistance.

MALAWI HAS AN HIV-1 PREVALENCE OF AROUND 12% (UNAIDS 2009). Although the prevalence is higher in urban areas, 80% of the population lives in rural areas, and the epidemic in these areas remains a concern and access to treatment more problematic. Over 200,000 people in Malawi have been on antiretroviral therapy (ART) and approximately 147,000 are currently on treatment.¹ Around 95% of them are on first-line therapy, 4% are on alternative first-line therapy, and less than 1% are on second-line therapy.¹ A fundamental concern of antiretroviral drug delivery programs is the avoidance of the development of widespread drug resistance. Drug resistance mutations (DRMs) have been primarily characterized for subtype B, which is predominant in America, Europe, and Australia where ART has been available for a decade and half, and where approximately 10% of new HIV infections are with drug-resistant isolates.² Fewer studies have characterized drug resistance in subtype C, which is responsible for more than 50% of worldwide infections. However, minor mutations associated with drug resistance have been reported in HIV-1 subtype C-infected drug-naive patients in a number of African locations including Malawi, and the percentage of drug-naive individuals harboring HIV with DRMs thus far has been shown to vary between 2% and 10%.³⁻⁶ Further characterization of drug resistance mutations in subtype-C HIV-1 and monitoring for transmission of drug-

resistant strains are extremely important both given the more recent wide-scale availability of ART in countries in which subtype C is predominant, and as the prevalence of non-B HIV-1 increases in countries in which antiretroviral drugs are widely used.

Karonga District is the northernmost district of Malawi and HIV-1 subtype C has been reported to be the most predominant subtype in this District.⁷ ART drugs were introduced in Malawi first in the context of prevention of maternal-to-child transmission (PMTCT) through antenatal clinics (using a mother and child nevirapine regime, which is ongoing). Full ART first became available at public clinics in the two major cities in Malawi in 2003, in the regional capital in 2004, and at Karonga district hospital in June 2005, at which time Karonga residents who had been seeking care outside the district were transferred to local services. ART delivery has been largely based on clinical assessment with CD4 counting becoming available in January 2008 at one clinic. Viral load assessment and routine drug resistance testing are not available and the baseline genotype of the genes, which are the targets for ART, are unknown. The objective of this study was to investigate the presence of polymorphisms associated with drug resistance found in the reverse transcriptase (RT) and protease (PR) regions and to explore the inpatient diversity of HIV-1 in these gene regions at a time when most individuals seen are

¹Zoology Department, Martin Ryan Institute, School of Natural Sciences, National University of Ireland, Galway, Ireland.

²South African National Bioinformatics Institute, University of the Western Cape, Bellville, South Africa.

³Karonga Prevention Study, Chilumba, Malawi.

⁴Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, United Kingdom.

drug naive and transmission of drug resistance from ART-treated individuals should be uncommon.

DNA was extracted from blood samples from 71 individuals living in Karonga District, Malawi using the QIAamp DNA Blood Mini Kit (QIAGEN Ltd). Extracted DNA was subjected to nested polymerase chain reaction (PCR) amplification of the HIV-1 PR and RT genes employing the primers previously described.⁶ The PCR mixture contained 1.5 mM MgCl₂, 1.5 units of *Taq* (Roche Expand High Fidelity PCR system), 0.8 mM each dNTP, and 5 pM primers (Eurofins MWG Operon). The cycling conditions were as follows: "hotstart" at 98°C for 1 min, primary denaturation at 94°C for 2 min followed by 35 cycles with 1 min denaturation at 94°C, 1 min annealing at 42°C, 4 min extension at 72°C, and final extension for 7 min at 72°C. For each gene region from 10 samples two PCR amplifications were pooled and the mixture cloned using the TOPO Cloning Kit (Invitrogen). Colony PCR and sequencing were carried out on 30 colonies per sample. Sequences obtained were edited in SeqMan (Lasergene, DNASTAR, Inc) and aligned using MacClade 4.0 (Sinauer Associates).

Preliminary phylogenetic analyses were first carried out to identify the subtype status of all sequences generated. Subsequently all consensus and clonal sequences that were subtype C were assembled into multiple alignments for each gene region using MacClade 4.0. Phylogenetic trees were reconstructed using the LANL (www.hiv.lanl.gov/content/index) subtype C ancestral sequence as outgroup under the GTR + gamma model of DNA substitution implemented RAXML 7.0.3⁸ with all parameters optimized by RAXML. Confidence levels in the groupings in the phylogeny were assessed using 1000 bootstrap replicates as part of the RAXML phylogeny reconstruction. To evaluate the effect of DRMs on clustering of individual sequences, analyses were also carried out with all sites showing the presence of DRMs removed. Sequences were submitted for analysis of DRMs to the Stanford Database (<http://hivdb.stanford.edu>).

Of the 71 DNA samples, amplification and sequencing were successful from 62 for RT and from 53 for PR. Three RT and six PR sequences were excluded from analysis because of poor quality and four individuals were infected with non-subtype C virus (no DRMs were present in these non-C sequences). For both gene fragments from subtype C strains phylogenetic analyses with and without DRMs present showed identical tree topologies indicating that sharing the same DRM was not, by itself, responsible for individual sequences clustering together. Figure 1 shows the relationships between sequences with DRMs included.

RTsequences included sequences from 40 individuals who were drug naive and from 17 who had been on ART. None of the drug-exposed individuals showed any DRMs, however, five (5/40) drug-naïve individuals showed nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations and four (4/40) showed non-NRTI (NNRTI) resistance mutations with both types of drug resistance mutations found in one individual (Table 1). The NRTI mutations found were V75LV (one individual) and V118I (four individuals) with five NNRTI mutations identified (A98G, K101Q, V106LV, E138A, and G190R) (Table 1). V118I occurs in ~2% of untreated persons infected with subtype C and with increased frequency in persons receiving multiple NRTIs.⁹ It causes low-level resistance to 3TC and possibly to other NRTIs when present with

TABLE 1. MUTATIONS ASSOCIATED WITH ANTIRETROVIRAL DRUG RESISTANCE FOUND IN CONSENSUS SEQUENCES FROM HIV⁺ INDIVIDUALS FROM KARONGA DISTRICT MALAWI^a

	<i>Reverse transcriptase</i>		
<i>Sample no.</i>	<i>NRTI</i>	<i>NNRTI</i>	<i>Protease</i>
Drug exposed			
54302	No sequence		T74S
53972	No sequence		L76S
53278	None	None	T74S
53974	None	None	L10V, T74S
Drug naïve			
54208	No sequence		T74S
53394	V118I	None	None
53436	V118I	None	No sequence
53733	V118I	None	No sequence
53900	V118I	None	None
54434	V75LV	V106LV	None
53977	None	None	T74S
54023	None	K101Q, E138A	T74S
54117	None	G190R	None
54357	None	A98G	No sequence

^aMutations involved in resistance to NRTI and NNRTI drugs and minor mutations involved in resistance to protease inhibitors are shown. The four shown in bold were previously drug exposed prior to enrolling in the study.

other mutations.¹⁰ This was the only mutation found in both previous studies of drug resistance mutations in Malawi, being present in 4 of 21 individuals studied by Petch *et al.*³ and 15 of 96 individuals with confirmed virologic failure by Hosseinipour *et al.*¹¹ Of the other drug resistance mutations found K101Q minimally reduces susceptibility to each of the NNRTIs, whereas mutation at position 75 (V75T/M/A/I) is associated with reduced NRTI susceptibility (<http://hivdb.stanford.edu>).

According to the Stanford database G190R is a highly unusual mutation and is flagged as an NNRTI resistance mutation. Little seems to be known about the effects of this mutation as yet in subtype C but G190A/S/E/Q/T/V/C are NNRTI resistance mutations. Similarly, although V106A causes high-level resistance to NVP and DLV and low to intermediate resistance to EFV, V106L is a rare polymorphism and its association with NNRTI resistance is less clear; E138A is responsible for decreased ETR response and A98G reduces NVP susceptibility by two- to threefold (<http://hivdb.stanford.edu>).

Cloning was successful for seven samples (Table 2). From individuals whose consensus sequence showed neither NRTI nor NNRTI drug resistance mutations, none of the clonal sequences generated showed drug resistance mutations (Table 2). All cloned sequences obtained from individual 53733 contained the NRTI V118I mutation that was found in the consensus sequence and one clonal sequence showed an additional L74K NRTI-resistant mutation. The consensus sequence retrieved from individual 54117 showed a G190R (NNRTI) mutation and also had four stop codons at positions 71, 88, 212, and 239 (according to HXB2 RT gene). All clones obtained from this individual showed the same four stop codons and the same G190R mutation. This study utilized proviral DNA to generate RT and PR sequences due to the




TABLE 2. SUMMARY OF AMINO ACID DIVERSITY IN MULTIPLE SEQUENCES RETRIEVED FROM INDIVIDUALS SHOWING EVIDENCE OF NRTI AND NNRTI RESISTANCE MUTATIONS IN THE ORIGINAL CONSENSUS SEQUENCE AND FROM THOSE THAT DID NOT^a

Sample no.	Mutation in original sequence		Number of cloned sequences obtained	NRTI mutations found in clones	NNRTI mutations found in clones
	NRTI	NNRTI			
53277	None	None	1	None	None
53213	None	None	27	None	None
53218	None	None	26	None	None
53889 ^b	None	None	27	None	None
53733	V118I	None	18	L74K, V118I	None
53900	V118I	None	24	V118I	None
54117 ^c	None	G190R	20	None	G190R

^aDrug-exposed individuals are in bold.

^bConsensus sequence was different from each of the clones.

^cAll clones and consensus contained four stop codons.

difficulty of working with RNA in this context (i.e., getting samples from a large population study in rural Africa). HIV-1 with a G–A hypermutation at positions 88 and 212 has previously been found in resting CD4 cells and the resulting DNA is reported to be degraded or defective.^{12,13} It is possible that the plasma of this individual would yield functional HIV-1. It is also possible that the individual may be infected with a defective virus and that this might affect disease progression.

The phylogenetic relationships of the RT sequences from most individuals were straightforward with both the clonal and consensus sequences grouping together in monophyletic groups, with high bootstrap support (Fig. 1a). The clones and the consensus sequence from 53733 appear to be ancestral to the virus infecting individual 53900 with both of these individuals infected with viral strains containing the same NRTI DRM (V118I). There is no known epidemiological link between these individuals. The laboratory work on these samples was carried out by different people and therefore contamination is not likely in this case. Of the individuals for whom the PCR products were not cloned there is only one instance of clustering of sequences containing DRMs with high bootstrap support (see the asterisk in Fig. 1a). One of these individuals is a male and the other is a female. These

individuals are in the same reporting group and thus may live geographically close together.

Of 45 subtype C protease sequences, 16 were from drug-exposed individuals and 29 were from drug-naïve individuals. Seven consensus sequences showed minor PI mutations including three from drug-naïve individuals (Table 1). Cloning was successful for eight samples, three for which the consensus had shown minor resistance sites and five for which the consensus showed no drug resistance mutations. Three drug-exposed individuals (53278, 54302, and 53974) showed minor PR resistance mutations in clonal sequences that were not seen in the consensus sequences, whereas 53278 also showed evidence of major PR resistance mutations in the sequenced clones (Table 3). Furthermore, this pattern was repeated among the drug-naïve individuals with major and minor DRMs present in clones that were not present in the consensus sequence (Table 3). Clones of 53278 showed major mutations D30N, M46I, and I84T. D30N causes high-level resistance to NFV and potential low-level resistance to ATV. M46I decreases susceptibility to IDV, NFV, FPV, LPV, and ATV when present with other mutations. I84V causes intermediate to high-level resistance to various PIs. Minor mutations at position 10 (L10I/V/F/R/Y) are associated with

TABLE 3. SUMMARY OF AMINO ACID DIVERSITY IN MULTIPLE SEQUENCES RETRIEVED FROM INDIVIDUALS SHOWING EVIDENCE OF PROTEASE INHIBITOR RESISTANCE MUTATIONS IN THE ORIGINAL CONSENSUS SEQUENCE AND FROM THOSE THAT DID NOT^a

Sample no.	Mutation in original sequence		Number of cloned sequences obtained	PI resistance major mutations found in clones	PI resistance minor mutations found in clones
	Major	Minor			
53278	None	T74S	14	D30N, M46I, I84T	G48R, T74S
53354	None	None	9	None	None
53974	None	L10V, T74S	29	None	L10V, G48R, T74S
54023	None	T74S	25	None	M46T, T74S
53394	None	None	28	None	None
53431	None	None	30	None	None
53843	None	None	30	None	None
54094	None	None	23	I47M	None

^aDrug-exposed individuals are in bold.

resistance to most PIs when present with other mutations and mutation at this site occurs in 5–10% of untreated persons including subtype C-infected individuals in Africa.^{4,5,11,14} Mutation at position 74 (T74S) is associated with reduced NFV susceptibility whereas mutation at position 76 (L76V) reduces susceptibility to FPV, IDV, LPV, and DRV and increases susceptibility to SQV, ATV, and TPV.^{14,15}

For most individuals phylogenetic relationships between the sequences were uncomplicated; however, while 10 clones and the consensus sequence from individual 53278 clustered closely and all showed the T74S minor PI mutation, sequences of three variants clustered together in the tree with sequences retrieved from a different individual with whom she has no known epidemiological links (Fig. 1b) rather than with other 53278 sequences. These three sequence variants were those that showed major PR inhibitor resistance mutations. Furthermore, none of these three variants showed the original T74S mutation but did show another minor PI mutation (G48R). One additional clone sequence was found clustering with clonal sequences from another female, 54023, again with whom she had no known link.

This work clearly shows the presence of both NRTI and NNRTI drug resistance mutations and the presence of minor and major PR resistance mutations in a number of drug-naïve individuals in rural Malawi in 2008 3 years after ART became widely available in the district. We have also shown the importance of sequencing multiple HIV-1 variants from individuals to fully assess drug resistance, as a number of individuals have shown major and/or minor drug resistance mutations in sequenced clones that were not present in the consensus sequences. Sequencing multiple clones of RT and PR from 16 individuals showed that one of them (female, aged 52, 53278 in Fig. 1b) was dual infected and showed evidence of being infected with viruses containing DRMs. The dual infection was confirmed by sequencing of multiple clones of the *gag* gene as part of another project, which showed a similar pattern of multiple lineages for this individual (Seager, unpublished). In terms of identifying possible transmission events involving HIV-1 with DRMs, apart from the dually infected individual mentioned above, there are very few cases of clustering of sequences from individuals with DRMs.

Our analyses showed that the presence of DRMs alone was not responsible for the pattern of relationships shown on the trees indicating common ancestry rather than convergence. However, given the short length of gene fragments used to explore drug resistance and in many cases having sequence evidence from only one gene, such results are not reliable reports of transmission and sequencing of additional loci is underway to confirm transmission in each case.

The presence of drug-resistant mutations in drug-naïve individuals may prevent successful treatment of certain individuals. This knowledge may also inform policymakers in planning future therapy strategies as this indicates that additional therapy combinations may be required. Although antiretroviral drugs were made more widely available in Karonga District in June 2005, prior to this NVP was available for the PMTCT in antenatal clinics and full ART would have been available to a number of individuals elsewhere in Malawi in 2002. Thus, it is also possible that some individuals assumed to be drug naïve did not disclose (or in the case of PMTCT were not aware of) ART exposure, and did not appear in the ART study cohorts. Furthermore, the presence

of DRMs in drug-naïve persons may represent natural polymorphisms and may not be suggestive of transmission of DRMs. The impact of such natural polymorphisms on the development of drug resistance in those people at commencement of ART is unknown and such individuals need to be monitored. Indeed the impact of such polymorphisms on the HIV-1 subtype C-infected population and the speed of more widespread drug resistance are also unknown. Therefore it may be important to further examine some of the individuals and mutations found during this study in view of a long-term treatment strategy in the district.

Sequence Data

All sequences have been deposited into GenBank, accession numbers HQ159410–HQ159841, and alignments employed in this work are available from the authors on request.

Acknowledgments

This material is based upon works supported by Science Foundation Ireland under Grant No. 07/RFP/EEEOBF424 and 08/UR/B1350. The Karonga Prevention Study is funded primarily by the Wellcome Trust, with contributions from LEPR. Permission for the study was received from the National Health Sciences Research Committee, Malawi, and the Ethics Committee of the London School of Hygiene and Tropical Medicine, UK.

Author Disclosure Statement

No competing financial interests exist.

References

1. Ministry of Health: Antiretroviral Treatment Programme in MALAWI. Annual report.
2. Hemelaar J, Gouws E, Ghys PD, and Osmanov S: Global and regional distribution of HIV-1 genetic subtypes and recombinants in 2004. *AIDS* 2006;20:W13–23.
3. Petch LA, Hoffman IF, Jere CS, *et al.*: Genotypic analysis of the protease and reverse transcriptase of HIV type 1 subtype C isolates from antiretroviral drug-naïve adults in Malawi. *AIDS Res Hum Retroviruses* 2005;21:799–805.
4. Kassu A, Fujino M, Matsuda M, Nishizawa M, Ota F, and Sugiura W: Molecular epidemiology of HIV type 1 in treatment-naïve patients in north Ethiopia. *AIDS Res Hum Retroviruses* 2007;23:564–568.
5. Bessong PO, Mphahlele J, Choge IA, *et al.*: Resistance mutational analysis of HIV type 1 subtype C among rural South African drug-naïve patients prior to large-scale availability of antiretrovirals. *AIDS Res Hum Retroviruses* 2006;22:1306–1312.
6. Handema R, Terunuma H, Kasolo F, *et al.*: Prevalence of drug-resistance-associated mutations in antiretroviral drug-naïve Zambians infected with subtype C HIV-1. *AIDS Res Hum Retroviruses* 2003;19:151–160.
7. McCormack G, Glynn JR, Crampin AC, *et al.*: Early evolution of the human immunodeficiency virus type 1 subtype C epidemic in rural Malawi. *J Virol* 2002;76:12890–12899.
8. Stamatakis A: RAXML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models. *Bioinformatics* 2006;22:2688–2690.
9. Rhee SY, Gonzales MJ, Kantor R, Betts BJ, Ravela J, and Shafer RW: Human immunodeficiency virus reverse

- transcriptase and protease sequence database. *Nucleic Acids Res* 2003;31:298–303.
10. Rhee SY, Kantor R, Katzenstein DA, *et al.*: HIV-1 pol mutation frequency by subtype and treatment experience: Extension of the HIVseq program to seven non-B subtypes. *AIDS* 2006;20:643–651.
 11. Hosseinipour MC, van Oosterhout JJ, Weigel R, *et al.*: The public health approach to identify antiretroviral therapy failure: High-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. *AIDS* 2009;23:1127–1134.
 12. Kieffer TL, Kwon P, Nettles RE, Han Y, Ray SC, and Sliciano RF: G → A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. *J Virol* 2005;79:1975–1980.
 13. Goff SP: Death by deamination: A novel host restriction system for HIV-1. *Cell* 2003;114:281–283.
 14. Vidal N, Niyongabo T, Nduwimana J, *et al.*: HIV type 1 diversity and antiretroviral drug resistance mutations in Burundi. *AIDS Res Hum Retroviruses* 2007;23:175–180.
 15. Somi GR, Kibuka T, Diallo K, *et al.*: Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania. *Antivir Ther* 2008;13(Suppl 2):77–82.

Address correspondence to:

Grace McCormack
Molecular Evolution & Systematics Laboratory
Zoology Department
Martin Ryan Institute
School of Natural Sciences
National University of Ireland
Galway
Ireland

E-mail: Grace.mccormack@nuigalway.ie